The Role of Checkpoint Inhibitors and Cytokines in Adoptive Cell-Based Cancer Immunotherapy with Genetically Modified T Cells

HER2 CAR-T cells eradicate uveal melanoma and T cell therapy-resistant human melanoma in interleukin-2 (IL-2) transgenic NOD/SCID IL-2 receptor knockout mice

(2019) Elin MV Forsberg et al.   CANCER RESEARCH

Short-term culture with IL-2 is beneficial for potent memory chimeric antigen receptor T cell production

(2018) Xuhua Zhang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Targeting the microenvironment in solid tumors

(2018) Carmen Belli et al.   CANCER TREATMENT REVIEWS

Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward

(2018) Jian Li et al.   Journal of Hematology & Oncology

The application of CAR-T cell therapy in hematological malignancies: Advantages and challenges

(2018) Zijun Zhao et al.   Acta Pharmaceutica Sinica B

Cytokine release syndrome: grading, modeling, and new therapy

(2018) Delong Liu et al.   Journal of Hematology & Oncology

CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies

(2018) Hannah M. Knochelmann et al.   Frontiers in Immunology

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma

(2017) Andras Heczey et al.   MOLECULAR THERAPY

CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond

(2017) ZeNan L. Chang et al.   TRENDS IN MOLECULAR MEDICINE

Global Manufacturing of CAR T Cell Therapy

(2017) Bruce L. Levine et al.   Molecular Therapy-Methods & Clinical Development

Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy

(2016) Oladapo O. Yeku et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy

(2016) Christoph Domschke et al.   Breast Care

Chimeric antigen receptors: driving immunology towards synthetic biology

(2016) Michel Sadelain   CURRENT OPINION IN IMMUNOLOGY

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

(2016) Leonid Cherkassky et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells

(2016) Partow Kebriaei et al.   JOURNAL OF CLINICAL INVESTIGATION

Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease

(2016) Jennifer N. Brudno et al.   JOURNAL OF CLINICAL ONCOLOGY

A short CD3/CD28 costimulation combined with IL-21 enhance the generation of human memory stem T cells for adoptive immunotherapy

(2016) C. Alvarez-Fernández et al.   Journal of Translational Medicine

Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors

(2016) R Monjezi et al.   LEUKEMIA

GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade

(2016) Tessa Gargett et al.   MOLECULAR THERAPY

Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response

(2016) Richard P. Junghans et al.   PROSTATE

Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model

(2016) Eloah Rabello Suarez et al.   Oncotarget

PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia

(2015) F. McClanahan et al.   BLOOD

Low-cost generation of Good Manufacturing Practice–grade CD19-specific chimeric antigen receptor–expressing T cells using piggyBac gene transfer and patient-derived materials

(2015) Saumya Ramanayake et al.   CYTOTHERAPY

Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2

(2015) Tessa Gargett et al.   CYTOTHERAPY

Mechanisms and Αpplications of Ιnterleukins in Cancer Immunotherapy

(2015) Doxakis Anestakis et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

(2015) James N. Kochenderfer et al.   JOURNAL OF CLINICAL ONCOLOGY

Engineering CAR-T cells: Design concepts

(2015) Shivani Srivastava et al.   TRENDS IN IMMUNOLOGY

Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors

(2015) Nobuhiro Nishio et al.   OncoImmunology

Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15

(2014) Y. Xu et al.   BLOOD

Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors

(2014) E. K. Moon et al.   CLINICAL CANCER RESEARCH

The IL-2 cytokine family in cancer immunotherapy

(2014) Geok Choo Sim et al.   CYTOKINE & GROWTH FACTOR REVIEWS

IL-15 regulates Bcl-2 family members Bim and Mcl-1 through JAK/STAT and PI3K/AKT pathways in T cells

(2014) Aparna R. Shenoy et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Interleukin-21: a double-edged sword with therapeutic potential

(2014) Rosanne Spolski et al.   NATURE REVIEWS DRUG DISCOVERY

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chimeric Antigen Receptor Therapy for Cancer

(2013) David M. Barrett et al.   Annual Review of Medicine

CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma

(2013) M. Casucci et al.   BLOOD

CD3ζ-based chimeric antigen receptors mediate T cell activation viacis- andtrans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy

(2013) J. S. Bridgeman et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Interleukin-7 Mediates Selective Expansion of Tumor-redirected Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-cell Inhibition

(2013) S. K. Perna et al.   CLINICAL CANCER RESEARCH

Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells

(2013) L. B. John et al.   CLINICAL CANCER RESEARCH

The Basic Principles of Chimeric Antigen Receptor Design

(2013) Michel Sadelain et al.   Cancer Discovery

Efficacy and Safety of Sleeping Beauty Transposon-Mediated Gene Transfer in Preclinical Animal Studies

(2012) Perry B. Hackett et al.   CURRENT GENE THERAPY

Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells

(2012) J. Scholler et al.   Science Translational Medicine

Reprogramming CD19-Specific T Cells with IL-21 Signaling Can Improve Adoptive Immunotherapy of B-Lineage Malignancies

(2011) H. Singh et al.   CANCER RESEARCH

Interleukin 15 as a promising candidate for tumor immunotherapy

(2011) Marek Jakobisiak et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Nondividing Cells: A Safer Bet for Integrating Vectors?

(2011) Troy Brady et al.   MOLECULAR THERAPY

T cell exhaustion

(2011) E John Wherry   NATURE IMMUNOLOGY

Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans

(2010) Michael C. Jensen et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice

(2010) J. C. Markley et al.   BLOOD

Anti-GD3 Chimeric sFv-CD28/T-Cell Receptor   Designer T Cells for Treatment of Metastatic Melanoma and Other Neuroectodermal Tumors

(2010) A. S. Y. Lo et al.   CLINICAL CANCER RESEARCH

Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma

(2010) Mehmood H Hashmi et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Selective Expansion of Chimeric Antigen Receptor-targeted T-cells with Potent Effector Function using Interleukin-4

(2010) Scott Wilkie et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo

(2009) Michael C. Milone et al.   MOLECULAR THERAPY

Second-Generation Anti-Carcinoembryonic Antigen Designer T Cells Resist Activation-Induced Cell Death, Proliferate on Tumor Contact, Secrete Cytokines, and Exhibit Superior Antitumor Activity In vivo: A Preclinical Evaluation

(2008) P. C.R. Emtage et al.   CLINICAL CANCER RESEARCH

Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1

(2008) Salima Hacein-Bey-Abina et al.   JOURNAL OF CLINICAL INVESTIGATION